Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
NCT ID: NCT06372483
Last Updated: 2024-11-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-02-21
Study Completion Date
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts:
Part 1: Single dose of VMX-C001 or placebo in healthy volunteers.
Part 2: Single dose of VMX-C001 or placebo in combination with a selected factor 10a (FXa) direct oral anticoagulant (DOAC) in healthy older subjects.
Part 1: Single dose of VMX-C001 or placebo in healthy volunteers.
Part 2: Single dose of VMX-C001 or placebo in combination with a selected factor 10a (FXa) direct oral anticoagulant (DOAC) in healthy older subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
NCT05152420
Coagulation Disorder
COMPLETED
PHASE1
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
NCT06517563
Coagulation Disorder
ACTIVE_NOT_RECRUITING
PHASE1
Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
NCT07288489
Blood Loss, Surgical
Coagulation Disorder
NOT_YET_RECRUITING
PHASE3
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT03218241
Healthy
COMPLETED
PHASE1
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT01758432
Healthy Volunteers
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coagulation Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Placebo controlled, single dose.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Double-blind
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1, Cohort 1:1 - VMX-C001
Single dose active.
Group Type
EXPERIMENTAL
VMX-C001
Intervention Type
DRUG
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Part 1, Cohort 1:1 - Placebo
Single dose placebo.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
VMX-C001 matched placebo
Part 2, Cohort 2:1 - VMX-C001 + Rivaroxaban
Single dose active in combination with DOAC.
Group Type
EXPERIMENTAL
VMX-C001
Intervention Type
DRUG
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:1 - Placebo + Rivaroxaban
Single dose placebo in combination with DOAC.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
VMX-C001 matched placebo
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:2 - VMX-C001 + DOAC
Optional cohort - Single dose active in combination with selected DOAC.
Group Type
EXPERIMENTAL
VMX-C001
Intervention Type
DRUG
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:2 - Placebo + DOAC
Optional cohort - Single dose placebo in combination with selected DOAC.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
VMX-C001 matched placebo
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:3 - VMX-C001 + DOAC
Optional cohort - Single dose active in combination with selected DOAC.
Group Type
EXPERIMENTAL
VMX-C001
Intervention Type
DRUG
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:3 - Placebo + DOAC
Optional cohort - Single dose placebo in combination with selected DOAC.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
VMX-C001 matched placebo
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:4 - VMX-C001 + DOAC
Optional cohort - Single dose active in combination with selected DOAC.
Group Type
EXPERIMENTAL
VMX-C001
Intervention Type
DRUG
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Part 2, Cohort 2:4 - Placebo + DOAC
Optional cohort - Single dose placebo in combination with selected DOAC.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
VMX-C001 matched placebo
Rivaroxaban 20 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Apixaban 5 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Edoxaban 60 mg Oral Tablet
Intervention Type
DRUG
Fxa DOAC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VMX-C001
VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Intervention Type
DRUG
Placebo
VMX-C001 matched placebo
Intervention Type
DRUG
Rivaroxaban 20 mg Oral Tablet
Fxa DOAC
Intervention Type
DRUG
Apixaban 5 mg Oral Tablet
Fxa DOAC
Intervention Type
DRUG
Edoxaban 60 mg Oral Tablet
Fxa DOAC
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. In Part 1, men and women of any ethnic origin between 18 and 49 years of age, in Part 2, men and women of any ethnic origin between 50 and 79 years of age, inclusive, at the time of Screening.
2. Male subjects must be willing to use appropriate contraception, such as a condom, and to refrain from sperm donation during the study and until 90 days after study drug administration.
3. Women of child-bearing potential must agree not to attempt to become pregnant and to use a highly effective form of birth control during the study and for 90 days after study drug administration when their sexual partner has not been vasectomized. Highly effective forms of birth control entail the use of combined (estrogen- and progestogen-containing) or progestogen-only hormonal contraception associated with inhibition of ovulation, an intrauterine device (IUD), an intrauterine hormone-releasing system (IUS) or abstinence.
4. Postmenopausal women must have had ≥12 months of spontaneous amenorrhea (with documented follicle-stimulating hormone (FSH) \>33.4 IU/L).
5. Surgically sterile women are defined as those who have had a surgical bilateral oophorectomy with or without hysterectomy, total hysterectomy or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, the reproductive status of the woman has to be confirmed by follow-up hormone level assessment. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
6. Subject must weigh between 60 and 120 kg, inclusive, and must have a BMI between 18.0 and 30.0 kg/m2, inclusive, at Screening and on Day -1.
7. Subject must be in good health, as determined by a medical history, physical examination, 12-lead ECG, and clinical laboratory evaluations (congenital non hemolytic hyperbilirubinemia is acceptable).
8. Subject is willing and able to give their written informed consent to participate in the study and to abide by the study restrictions.
9. Subject has good upper limb venous access.
2. Male subjects must be willing to use appropriate contraception, such as a condom, and to refrain from sperm donation during the study and until 90 days after study drug administration.
3. Women of child-bearing potential must agree not to attempt to become pregnant and to use a highly effective form of birth control during the study and for 90 days after study drug administration when their sexual partner has not been vasectomized. Highly effective forms of birth control entail the use of combined (estrogen- and progestogen-containing) or progestogen-only hormonal contraception associated with inhibition of ovulation, an intrauterine device (IUD), an intrauterine hormone-releasing system (IUS) or abstinence.
4. Postmenopausal women must have had ≥12 months of spontaneous amenorrhea (with documented follicle-stimulating hormone (FSH) \>33.4 IU/L).
5. Surgically sterile women are defined as those who have had a surgical bilateral oophorectomy with or without hysterectomy, total hysterectomy or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, the reproductive status of the woman has to be confirmed by follow-up hormone level assessment. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
6. Subject must weigh between 60 and 120 kg, inclusive, and must have a BMI between 18.0 and 30.0 kg/m2, inclusive, at Screening and on Day -1.
7. Subject must be in good health, as determined by a medical history, physical examination, 12-lead ECG, and clinical laboratory evaluations (congenital non hemolytic hyperbilirubinemia is acceptable).
8. Subject is willing and able to give their written informed consent to participate in the study and to abide by the study restrictions.
9. Subject has good upper limb venous access.
Exclusion Criteria
1. The subject has taken tenoxicam in the 35 days prior to the first administration of study drug or FXa DOAC or has taken piroxicam in the two weeks prior to the first administration of study drug or FXa DOAC.
2. The subject has taken any non-aspirin, non-piroxicam, non-steroidal anti-inflammatory drug (NSAID) in the week prior to the first administration of study drug or FXa DOAC.
3. The subject requires or has taken during the month prior to first administration of study drug or FXa DOAC, vitamin K for therapeutic reasons. Vitamin K not taken for therapeutic purposes is acceptable, e.g., as part of a multivitamin supplement.
4. The subject is receiving or requires, for any cause, any anticoagulant or antiplatelet therapy including warfarin, clopidogrel or aspirin or any other anticoagulant or antiplatelet agent or has used these therapies in the month prior to the first administration of study drug or FXa DOAC.
5. The subject has received any prescribed oral, systemic or topical medication, including any vaccinations, within 14 days prior to the first administration of study drug or FXa DOAC (with the exception of contraceptives), unless in the opinion of the Principal Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety.
6. The subject has used any non-prescribed systemic or topical medication (including herbal remedies) within one week prior to the first administration of study drug or FXa DOAC (with the exception of oral vitamin/mineral supplements \[including those that contain vitamin K when not taken for therapeutic purposes\] and paracetamol), unless in the opinion of the Principal Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety.
7. The subject is currently participating in a clinical study, e.g. attending follow-up visits or has been administered an investigational drug (new chemical or biological entity) within 1 month (for small molecules) or 3 months (for biologicals) prior to administration of the study drug.
8. The subject has donated ≥500 mL blood, plasma, or platelets in the 3 months prior to Screening or any other blood amount within 30 days prior to Screening.
9. Because of an increased risk of thrombosis subjects with known diabetes mellitus or a fasted glucose ≥7.0 mmol/L at Screening.
10. The subject has any bleeding diathesis, any increased risk of bleeding or, in the opinion of the Principal Investigator, is at increased risk of the consequences of bleeding including but not limited to the following:
1. gastro-intestinal ulceration within the last 3 months;
2. known or suspected oesophageal varices;
3. vascular aneurysms or known arteriovenous malformations;
4. history of known major intraspinal or intracerebral vascular abnormalities;
5. history of brain, spinal or ophthalmic surgery within the last year;
6. any intracranial hemorrhage;
7. uncontrolled severe hypertension.
11. The subject has, in the opinion of the Principal Investigator, any increased risk of thrombosis or thromboembolism including any known thrombophilia, such as antiphospholipid syndrome, or any past history of provoked or unprovoked arterial or venous thrombosis, including thromboembolism.
12. The subject has a significant history of drug allergy, as determined by the Principal Investigator.
13. The subject has at Screening or on Day -1, a supine blood pressure or supine pulse rate ≥ 150/95 mmHg and \>100 beats per minute (bpm), respectively, or \< 90/40 mmHg and 40 bpm, respectively, confirmed by a repeat assessment.
14. For Part 1, the subject consumes \>21 alcoholic drinks/week for men or \>14 alcoholic drinks/week for women (one unit of alcohol equals ½ pint \[285 mL\] of beer or lager, one glass \[125 mL\] of wine, or 1 measure \[25 mL\] of spirits) or has a significant history of alcoholism or drug/chemical abuse, as determined by the Principal Investigator. For Part 2, the subject consumes \>14 alcoholic drinks/week or has a significant history of alcoholism or drug/chemical abuse, as determined by the Principal Investigator.
15. The subject has a positive drug screen, alcohol test or cotinine test result at Screening or on Day -1, confirmed by repeat testing.
16. The female subject has a positive pregnancy test at Screening or on Day -1 or is lactating.
17. The subject currently smokes or uses nicotine-containing products. Former smokers will be eligible, provided they have not smoked for at least 1 month prior to administration of the study drug.
18. The subject has, or has a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological, or other major disorders, as determined by the Principal Investigator.
19. The subject has a positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody test result at Screening.
20. The subject has an abnormality in the 12-lead ECG at Screening or on Day -1 that, in the judgement of the Principal Investigator may, during the study, interfere with the interpretation of 12-lead ECG results, including average QTcF interval \>450 msec for men or \>470 msec for women, 2nd or 3rd degree atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolff-Parkinson-White Syndrome, defined as average PR\<110 msec, confirmed by a triplicate repeat ECG.
21. The subject has any other condition that, in the opinion of the Principal Investigator, would compromise the safety of the subject or the subject's ability to comply with the protocol and complete the study.
22. The subject has renal insufficiency (serum creatinine level \> 1.25 times upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) of \<60 mL/min\*1.73m2).
23. The subject has active liver disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>1.5x ULN, or total bilirubin \> 1.5x ULN at Screening or on Day -1. One re-test is allowed).
24. The subject has previously participated in a clinical study with VMX-C001.
25. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received medication that is an inhibitor of P-glycoprotein or CYP3A4. (e.g., clarithromycin, erythromycin and azole-antimycotics such as ketoconazole, itraconazole, voriconazole and osaconazole or HIV protease inhibitors.) within 30 days prior to first administration of FXa DOAC.
26. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received treatment with CYP3A4 inducers (e.g., St. John's wort, rifampicin, phenytoin, carbamazepine, phenobarbital) within 30 days prior to first administration of FXa DOAC.
27. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received treatment with selective serotonin reuptake inhibitors (SSRIs) or selective noradrenaline reuptake inhibitors (SNRIs) within 30 days prior to first administration of FXa DOAC.
28. The subject has any contra-indication to treatment with FXa DOACs.
2. The subject has taken any non-aspirin, non-piroxicam, non-steroidal anti-inflammatory drug (NSAID) in the week prior to the first administration of study drug or FXa DOAC.
3. The subject requires or has taken during the month prior to first administration of study drug or FXa DOAC, vitamin K for therapeutic reasons. Vitamin K not taken for therapeutic purposes is acceptable, e.g., as part of a multivitamin supplement.
4. The subject is receiving or requires, for any cause, any anticoagulant or antiplatelet therapy including warfarin, clopidogrel or aspirin or any other anticoagulant or antiplatelet agent or has used these therapies in the month prior to the first administration of study drug or FXa DOAC.
5. The subject has received any prescribed oral, systemic or topical medication, including any vaccinations, within 14 days prior to the first administration of study drug or FXa DOAC (with the exception of contraceptives), unless in the opinion of the Principal Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety.
6. The subject has used any non-prescribed systemic or topical medication (including herbal remedies) within one week prior to the first administration of study drug or FXa DOAC (with the exception of oral vitamin/mineral supplements \[including those that contain vitamin K when not taken for therapeutic purposes\] and paracetamol), unless in the opinion of the Principal Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety.
7. The subject is currently participating in a clinical study, e.g. attending follow-up visits or has been administered an investigational drug (new chemical or biological entity) within 1 month (for small molecules) or 3 months (for biologicals) prior to administration of the study drug.
8. The subject has donated ≥500 mL blood, plasma, or platelets in the 3 months prior to Screening or any other blood amount within 30 days prior to Screening.
9. Because of an increased risk of thrombosis subjects with known diabetes mellitus or a fasted glucose ≥7.0 mmol/L at Screening.
10. The subject has any bleeding diathesis, any increased risk of bleeding or, in the opinion of the Principal Investigator, is at increased risk of the consequences of bleeding including but not limited to the following:
1. gastro-intestinal ulceration within the last 3 months;
2. known or suspected oesophageal varices;
3. vascular aneurysms or known arteriovenous malformations;
4. history of known major intraspinal or intracerebral vascular abnormalities;
5. history of brain, spinal or ophthalmic surgery within the last year;
6. any intracranial hemorrhage;
7. uncontrolled severe hypertension.
11. The subject has, in the opinion of the Principal Investigator, any increased risk of thrombosis or thromboembolism including any known thrombophilia, such as antiphospholipid syndrome, or any past history of provoked or unprovoked arterial or venous thrombosis, including thromboembolism.
12. The subject has a significant history of drug allergy, as determined by the Principal Investigator.
13. The subject has at Screening or on Day -1, a supine blood pressure or supine pulse rate ≥ 150/95 mmHg and \>100 beats per minute (bpm), respectively, or \< 90/40 mmHg and 40 bpm, respectively, confirmed by a repeat assessment.
14. For Part 1, the subject consumes \>21 alcoholic drinks/week for men or \>14 alcoholic drinks/week for women (one unit of alcohol equals ½ pint \[285 mL\] of beer or lager, one glass \[125 mL\] of wine, or 1 measure \[25 mL\] of spirits) or has a significant history of alcoholism or drug/chemical abuse, as determined by the Principal Investigator. For Part 2, the subject consumes \>14 alcoholic drinks/week or has a significant history of alcoholism or drug/chemical abuse, as determined by the Principal Investigator.
15. The subject has a positive drug screen, alcohol test or cotinine test result at Screening or on Day -1, confirmed by repeat testing.
16. The female subject has a positive pregnancy test at Screening or on Day -1 or is lactating.
17. The subject currently smokes or uses nicotine-containing products. Former smokers will be eligible, provided they have not smoked for at least 1 month prior to administration of the study drug.
18. The subject has, or has a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological, or other major disorders, as determined by the Principal Investigator.
19. The subject has a positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody test result at Screening.
20. The subject has an abnormality in the 12-lead ECG at Screening or on Day -1 that, in the judgement of the Principal Investigator may, during the study, interfere with the interpretation of 12-lead ECG results, including average QTcF interval \>450 msec for men or \>470 msec for women, 2nd or 3rd degree atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolff-Parkinson-White Syndrome, defined as average PR\<110 msec, confirmed by a triplicate repeat ECG.
21. The subject has any other condition that, in the opinion of the Principal Investigator, would compromise the safety of the subject or the subject's ability to comply with the protocol and complete the study.
22. The subject has renal insufficiency (serum creatinine level \> 1.25 times upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) of \<60 mL/min\*1.73m2).
23. The subject has active liver disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>1.5x ULN, or total bilirubin \> 1.5x ULN at Screening or on Day -1. One re-test is allowed).
24. The subject has previously participated in a clinical study with VMX-C001.
25. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received medication that is an inhibitor of P-glycoprotein or CYP3A4. (e.g., clarithromycin, erythromycin and azole-antimycotics such as ketoconazole, itraconazole, voriconazole and osaconazole or HIV protease inhibitors.) within 30 days prior to first administration of FXa DOAC.
26. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received treatment with CYP3A4 inducers (e.g., St. John's wort, rifampicin, phenytoin, carbamazepine, phenobarbital) within 30 days prior to first administration of FXa DOAC.
27. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives or has received treatment with selective serotonin reuptake inhibitors (SSRIs) or selective noradrenaline reuptake inhibitors (SNRIs) within 30 days prior to first administration of FXa DOAC.
28. The subject has any contra-indication to treatment with FXa DOACs.
Minimum Eligible Age
18 Years
Maximum Eligible Age
79 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VarmX B.V.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ICON
Groningen, , Netherlands
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Netherlands
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-507059-32-00
Identifier Type: CTIS
Identifier Source: secondary_id
VMX-C001-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT03310021
COMPLETED
PHASE2
A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation
NCT06729034
NOT_YET_RECRUITING
PHASE2
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
NCT03083704
COMPLETED
PHASE1
DOAC - Dosing Options in AntiCoagulation Prophylaxis
NCT07005024
NOT_YET_RECRUITING
PHASE3
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00643201
COMPLETED
PHASE3
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
NCT00986635
COMPLETED
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT00402467
COMPLETED
PHASE2
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524
COMPLETED
PHASE2
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
NCT03330457
TERMINATED
PHASE2
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
NCT02933697
COMPLETED
PHASE3
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
NCT00633893
COMPLETED
PHASE3
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
NCT03456648
COMPLETED
PHASE2
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
NCT03812835
WITHDRAWN
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
NCT02720328
COMPLETED
PHASE4
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00375609
COMPLETED
PHASE2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
NCT07312851
NOT_YET_RECRUITING
PHASE1
Study Evaluating Betrixaban in Pediatric Participants
NCT03346083
TERMINATED
PHASE1
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03251482
COMPLETED
PHASE2
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780
COMPLETED
PHASE3
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
NCT04041843
COMPLETED
PHASE2
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
NCT00742859
COMPLETED
PHASE2
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
NCT00395772
COMPLETED
PHASE2
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
NCT01583218
COMPLETED
PHASE3